Dr Juan Vera’s email quoted as follows:
“Dear _______,
Thank you for your question and your ongoing interest in our company.
We understand the excitement and curiosity our press releases have generated among our shareholders.
The strategic review and restructuring of our clinical programs is a complex and meticulous process. It's not about one single program or research direction, but rather a holistic reconsideration of how our clinical programs are developed and carried out. As you can imagine, the announcement of such updates takes time until the changes are fully implemented. This includes the incorporation and consideration of numerous variables, such as the latest scientific developments and aligning with changing regulations. A significant part of this process also requires the coordination with study Principal Investigators (PIs) across the country to ensure that all the proposed changes are consistent with the overall objectives and the scientific integrity of the studies before they are integrated into our clinical protocols. Furthermore, communicating those changes to the U.S. FDA is a critical step that is performed with the utmost diligence. Until the FDA approves the changes to our study plans, we will not be able to share them with the public. This is to ensure that the integrity of our clinical programs is maintained and that all updates are in full compliance with regulatory standards.
Our team is working vigorously to implement these changes, and we are currently in the final stages of preparing this comprehensive review. Our recent press releases have given a sense of what changes to expect in Marker's revised clinical programs and provided a rough idea of the new directions and strategies we will be pursuing in the future. The broad outlines were intended to signal our commitment to innovation and improvement while maintaining the confidentiality required at this stage of the process.
We understand our shareholders' eagerness to learn more about our strategic developments and the future direction of Marker Therapeutics. Please be assured that we are working diligently to provide clear, comprehensive and timely information, and we are looking forward to sharing more about our exciting new directions in the coming weeks.
We remain committed to our mission of improving patient care through innovative immunotherapies, and we greatly appreciate your continued support and patience.
Best regards,
Juan”
AI
